Circulating tumor cells in gastric cancer

Nakamura, Kenichi; Iwatsuki, Masaaki; Kurashige, Junji; Ishimoto, Takatsugu; Baba, Yoshifumi; Miyamoto, Yuji; Yoshida, Naoya; Watanabe, Masayuki; Baba, Hideo

doi:10.20517/2394-4722.2017.78

Cited by 7 publications

(7 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on these findings, they speculated that the loss of TFF1 resulted in the epithelial-mesenchymal transition (EMT) of tumor cells and, therefore, upregulation of TFF1 might inhibit the EMT in cancer cells. During EMT, epithelial cells change their phenotype, exhibiting a reduction in cell-cell contacts, loss of polarity, increased cell motility and invasiveness, repression of epithelial cell markers (e.g., epithelial cells adhesion molecule (EpCAM), cytokeratin (CK), or E-cadherin), and aberrant upregulation of certain mesenchymal markers (e.g., vimentin and N-cadherin) [45]. Indeed, a recent study demonstrated that the overexpression of TFF1 inhibits EMT through regulation of TGF-β in gastric cancer cells.…”

Section: Discussionmentioning

confidence: 99%

Immunoexpression of Trefoil Factor 1 in Non-Neoplastic and Neoplastic Canine Gastric Tissues

Flores

Castro

Rêma

et al. 2021

Animals

View full text Add to dashboard Cite

TFF1 expression is markedly reduced in human GCs, suggesting that TFF1 is a tumor suppressor for human gastric cancer. The present study evaluated the expression and distribution pattern of TFF1 in paraffin-embedded canine gastric tissue samples, including normal mucosa (n = 3), polyps (n = 8), carcinomas (n = 31) and their adjacent non-neoplastic mucosa (n = 30), neoplastic emboli (n = 14), and metastatic lesions (n = 8), by immunohistochemistry (IHC). All normal gastric tissues expressed TFF1 in the superficial foveolar epithelium and mucopeptic cells of the neck region. Most gastric polyps (GPs) displayed immunoreactivity for TFF1 in >75% of the epithelial component. In GCs, the expression of TFF1 was found reduced in 74.2% of the cases. The level of TFF1 expression had a decreased tendency from normal gastric mucosa to GPs and GCs (p < 0.05). No significant differences in the expression of TFF1 were found in GCs, according to age, sex, histological type based on World Health Organization (WHO) and Lauren classification, tumor location, depth of tumor invasion, presence of neoplastic emboli or metastatic lesions. The median survival time of GC patients with preserved and reduced TFF1 immunoexpression were 30 and 12 days, respectively. Kaplan–Meier analysis revealed no significant survival differences between the two groups (p > 0.05). These findings suggest that TFF1 protein may play a role in canine gastric carcinogenesis, and further studies are necessary to define its usefulness as a prognostic indicator in canine gastric carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunoexpression of Trefoil Factor 1 in Non-Neoplastic and Neoplastic Canine Gastric Tissues

Flores

Castro

Rêma

et al. 2021

Animals

View full text Add to dashboard Cite

show abstract

“…CTCs are cancer cells that have been released either from the primary tumor site or from the metastatic sites [ 28 ]. Several meta-analyses have demonstrated an association between the presence of GC CTCs and advanced tumor stage, lymphatic invasion, and poorer survival [ 29 ]. There are various markers for gastric cancer CTCs; for the epithelial subtype, they include EpCAm, cytokeratin (CK): CK8, CK18, and CK19 and for the mesenchymal subtype, they include vimentin and twist [ 30 , 31 ].…”

Section: Diagnosismentioning

confidence: 99%

Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer

Haque

Esmail

Muhsen

et al. 2022

Cancers

View full text Add to dashboard Cite

Gastric cancer is an enigmatic malignancy that has recently been shown to be increasing in incidence globally. There has been recent progress in emerging technologies for the diagnosis and treatment of the disease. Improvements in non-invasive diagnostic techniques with serological tests and biomarkers have led to decreased use of invasive procedures such as endoscopy. A multidisciplinary approach is used to treat gastric cancer, with recent significant advancements in systemic therapies used in combination with cytotoxic chemotherapies. New therapeutic targets have been identified and clinical trials are taking place to assess their efficacy and safety. In this review, we provide an overview of the current and emerging treatment strategies and diagnostic techniques for gastric cancer.

show abstract

“…Currently used methods for CTC isolation include a primary step of enrichment consisting on depletion of red and white blood cells known as negative selection, and a positive selection based on their biological and physical properties, with subsequent identification supported by immunological, molecular, and functional markers. There are several enrichment technologies known, such as Cell Search, Adna Test, CTC-chip, MACS, or MagSweeper, all of them using epithelial cell adhesion molecule (EpCAM) as a surface marker for enrichment ( 8 ). The main issue is that during the metastasis process, involving migration, intravasation, circulation into the bloodstream, and extravasation with new organ colonization, CTCs undergo epithelial to mesenchymal transition (EMT) and lose their epithelial markers becoming more difficult to identify.…”

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 99%

Clinical Applications of Liquid Biopsy in Gastric Cancer

Chivu‐Economescu¹,

Necula²,

Matei³

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Liquid biopsy represents an exciting new area in the field of cancer diagnosis and management, offering a less invasive and more convenient approach to obtain a time-point image of the tumor burden and its genomic profile. Samples collected from several body fluids, mostly blood, can be used to gain access to circulating tumor cells and DNA, non-coding RNAs, microRNAs, and exosomes, at any moment, offering a dynamic picture of the tumor. For patients with GC, the use of blood-based biopsies may be particularly beneficial since tissue biopsies are difficult to obtain and cause real distress to the patient. With advantages such as repeatability and minimal invasion, it is no wonder that the field of liquid biopsy has received tremendous attention. However, the abundance of studies, involving a wide range of assays with different principles, prevented for the moment the reproducibility of the results and therefore the translation into the clinic of liquid biopsy. In this review, we present the latest technical development and data on circulating biomarkers available through liquid biopsy in gastric cancer with an emphasis on their clinical utility in areas such as cancer screening, prognostic stratification, and therapeutic management.

show abstract

Circulating tumor cells in gastric cancer

Cited by 7 publications

References 47 publications

Immunoexpression of Trefoil Factor 1 in Non-Neoplastic and Neoplastic Canine Gastric Tissues

Immunoexpression of Trefoil Factor 1 in Non-Neoplastic and Neoplastic Canine Gastric Tissues

Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer

Clinical Applications of Liquid Biopsy in Gastric Cancer

Contact Info

Product

Resources

About